Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies

Review

(2884) Views  (433) Full article downloads

Authors: Prashant Gajwani, David J Muzina, David E Kemp, Keming Gao, Joseph R Calabrese

Published Date January 2007 Volume 2007:3(6) Pages 847 - 853

DOI: http://dx.doi.org/10.2147/NDT.S1636

Prashant Gajwani¹, David J Muzina², David E Kemp³, Keming Gao¹, Joseph R Calabrese¹

¹Case Western Reserve University (CWRU) School of Medicine, ²Cleveland Clinic Lerner College of Medicine of CWRU, ³Case Western Reserve University, Cleveland OH, USA

Abstract: The essential features of bipolar affective disorder involve the cyclical occurrence of high (manic or hypomanic episodes) and low mood states. Depressive episodes in both bipolar I and II disorder are more numerous and last for longer duration than either manic or hypomanic episodes. In addition depressive episodes are associated with higher morbidity and mortality. While multiple agents, including all 5 atypical antipsychotics, have demonstrated efficacy and earned US FDA indication for manic phase of bipolar illness, the acute treatment of bipolar depression is less well-studied. The first treatment approved by the US FDA for acute bipolar depression was the combination of the atypical antipsychotic olanzapine and the antidepressant fluoxetine. Recently, quetiapine monotherapy has demonstrated efficacy in the treatment of depressive episodes associated with both bipolar I and II disorder and has earned US FDA indication for the same.

Keywords: bipolar disorder, quetiapine, BOLDER studies